These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
22. Interleukin-22: a potential therapeutic target in atherosclerosis. Luo JW; Hu Y; Liu J; Yang H; Huang P Mol Med; 2021 Aug; 27(1):88. PubMed ID: 34388961 [TBL] [Abstract][Full Text] [Related]
23. Interleukin-33: a novel mediator with a role in distinct disease pathologies. Kurowska-Stolarska M; Hueber A; Stolarski B; McInnes IB J Intern Med; 2011 Jan; 269(1):29-35. PubMed ID: 21158975 [TBL] [Abstract][Full Text] [Related]
24. Cytokines and immunodeficiency diseases: critical roles of the gamma(c)-dependent cytokines interleukins 2, 4, 7, 9, 15, and 21, and their signaling pathways. Kovanen PE; Leonard WJ Immunol Rev; 2004 Dec; 202():67-83. PubMed ID: 15546386 [TBL] [Abstract][Full Text] [Related]
25. The Interleukin-20 Cytokine Family in Liver Disease. Caparrós E; Francés R Front Immunol; 2018; 9():1155. PubMed ID: 29892294 [TBL] [Abstract][Full Text] [Related]
27. The roles of cytokines, inflammation and immunity in vascular diseases. Ohsuzu F J Atheroscler Thromb; 2004; 11(6):313-21. PubMed ID: 15644584 [TBL] [Abstract][Full Text] [Related]
28. Interleukin-32α Inhibits Endothelial Inflammation, Vascular Smooth Muscle Cell Activation, and Atherosclerosis by Upregulating Timp3 and Reck through suppressing microRNA-205 Biogenesis. Son DJ; Jung YY; Seo YS; Park H; Lee DH; Kim S; Roh YS; Han SB; Yoon DY; Hong JT Theranostics; 2017; 7(8):2186-2203. PubMed ID: 28740544 [TBL] [Abstract][Full Text] [Related]
29. Interleukins (ILs), a fascinating family of cytokines. Part I: ILs from IL-1 to IL-19. Fietta P; Costa E; Delsante G Theor Biol Forum; 2014; 107(1-2):13-45. PubMed ID: 25936211 [TBL] [Abstract][Full Text] [Related]
30. Role of pro- and anti-inflammatory cytokines during inflammation: experimental and clinical findings. Dinarello CA J Biol Regul Homeost Agents; 1997; 11(3):91-103. PubMed ID: 9498158 [TBL] [Abstract][Full Text] [Related]
32. [The biological function and significance of IL-35 in the pathogenesis of atherosclerosis]. Staciwa M; Broncel M Pol Merkur Lekarski; 2018 Apr; 44(262):161-164. PubMed ID: 29775441 [TBL] [Abstract][Full Text] [Related]
33. The emergence of the IL-36 cytokine family as novel targets for inflammatory diseases. Walsh PT; Fallon PG Ann N Y Acad Sci; 2018 Apr; 1417(1):23-34. PubMed ID: 27783881 [TBL] [Abstract][Full Text] [Related]
34. IL-36, IL-37, and IL-38 Cytokines in Skin and Joint Inflammation: A Comprehensive Review of Their Therapeutic Potential. Boutet MA; Nerviani A; Pitzalis C Int J Mol Sci; 2019 Mar; 20(6):. PubMed ID: 30871134 [TBL] [Abstract][Full Text] [Related]
35. Interleukin 32, inflammation and cancer. Hong JT; Son DJ; Lee CK; Yoon DY; Lee DH; Park MH Pharmacol Ther; 2017 Jun; 174():127-137. PubMed ID: 28223235 [TBL] [Abstract][Full Text] [Related]
36. The novel interleukin-1 cytokine family members in inflammatory diseases. Hahn M; Frey S; Hueber AJ Curr Opin Rheumatol; 2017 Mar; 29(2):208-213. PubMed ID: 27926540 [TBL] [Abstract][Full Text] [Related]
38. Conflicting vascular and metabolic impact of the IL-33/sST2 axis. Altara R; Ghali R; Mallat Z; Cataliotti A; Booz GW; Zouein FA Cardiovasc Res; 2018 Oct; 114(12):1578-1594. PubMed ID: 29982301 [TBL] [Abstract][Full Text] [Related]
39. Functional biology of the IL-22-IL-22R pathway in regulating immunity and inflammation at barrier surfaces. Sonnenberg GF; Fouser LA; Artis D Adv Immunol; 2010; 107():1-29. PubMed ID: 21034969 [TBL] [Abstract][Full Text] [Related]
40. Regulation of innate and adaptive immune responses by the related cytokines IL-12, IL-23, and IL-27. Beadling C; Slifka MK Arch Immunol Ther Exp (Warsz); 2006; 54(1):15-24. PubMed ID: 16642253 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]